The United Kingdom and the United States have signed a important trade agreement that will maintain no tariffs on British drug shipments entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to raise expenditure on medicines through the public health system. This move guarantees that import taxes on these key goods will stay at nothing for a period of three years.
This deal comes after recent statements to dramatically increase import taxes on patented drug imports, with figures mentioned up to one hundred percent.
"This arrangement with the Britain reinforces the worldwide climate for innovative medicines and introduces much-needed fairness to American-British medicine commerce," a release declared.
Economic Impact
Drugs are one of the UK's most significant export categories to the US, which is easily the primary buyer for large UK drugmakers.
Trade data reveal that in the 12 months leading up to last September, the UK exported medicines worth billions to the US. This figure made up 17.4% of total UK exports in that span.
"This agreement protects employment, stimulates funding and facilitates the UK to become a international leader for life sciences," a minister stated.
Specific UK Commitments
The pact entails several specific pledges from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double overall health service expenditure on drugs from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to control costs will be capped at 15%. Last year, rebates topped twenty percent.
Recent Tensions
This agreement comes amid a ongoing tension between the sector and the British authorities over drug pricing and NHS adoption.
The disagreement were intensified by assertions that American customers were charged a premium for the equivalent treatments than people in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward American operations.
A senior figure acknowledged that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the past decade.
